Amended August 18, 2015 Planned Parenthood of the Heartland, Inc. and Jill Meadows v. Iowa Board of Medicine

CourtSupreme Court of Iowa
DecidedJune 19, 2015
Docket14–1415
StatusPublished

This text of Amended August 18, 2015 Planned Parenthood of the Heartland, Inc. and Jill Meadows v. Iowa Board of Medicine (Amended August 18, 2015 Planned Parenthood of the Heartland, Inc. and Jill Meadows v. Iowa Board of Medicine) is published on Counsel Stack Legal Research, covering Supreme Court of Iowa primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Amended August 18, 2015 Planned Parenthood of the Heartland, Inc. and Jill Meadows v. Iowa Board of Medicine, (iowa 2015).

Opinion

IN THE SUPREME COURT OF IOWA No. 14–1415

Filed June 19, 2015

Amended August 18, 2015

PLANNED PARENTHOOD OF THE HEARTLAND, INC. and JILL MEADOWS,

Appellants,

vs.

IOWA BOARD OF MEDICINE,

Appellee.

Appeal from the Iowa District Court for Polk County, Jeffrey D.

Farrell, Judge.

Providers appeal a district court judgment upholding a rule by the

Iowa Board of Medicine establishing standards of practice for physicians

who prescribe or administer abortion-inducing drugs. AFFIRMED IN

PART AND REVERSED IN PART.

Alice Clapman of Planned Parenthood Federation of America,

Washington, D.C., Sharon K. Malheiro of Davis, Brown, Koehn, Shors &

Roberts, P.C., Des Moines, and Roger Evans of Planned Parenthood

Federation of America, New York, New York, for appellant.

Thomas J. Miller, Attorney General, Jeffrey S. Thompson, Solicitor

General, and Julie J. Bussanmas and Meghan L. Gavin, Assistant

Attorneys General, for appellee. 2

Paige Fiedler of Fiedler & Timmer, P.L.L.C., Urbandale, and

Holly A. Harrison, Lynn D. Fleisher, Ph.D., Patrick E. Croke, Daniel C.

Craig, and Andrew Chinsky of Sidley Austin LLP, Chicago, Illinois, for

amicus curiae American College of Obstetricians and Gynecologists.

Roxanne Barton Conlin of Roxanne Conlin & Associates, P.C.,

Des Moines, for amici curiae Iowa Coalition Against Sexual Assault, Iowa

Coalition Against Domestic Violence, and National Women’s Law Center.

Joe Austen of Austen Law Office, PLLC, West Des Moines, and Rita

Bettis of ACLU of Iowa, Des Moines, for amicus curiae American Civil

Liberties Union of Iowa.

Mailee R. Smith of Americans United for Life, Washington, D.C.,

and Arthur F. Gilloon of Gilloon, Wright & Hamel PC, Dubuque, for amici

curiae Physicians for Life, National Association of Pro Life Nurses,

Christian Medical Association, National Association of Catholic Nurses,

and The National Catholic Bioethics Center.

Timm Reid of Galligan & Reid, P.C., Des Moines, and Michael J.

Norton and Natalie L. Decker of Alliance Defending Freedom, Greenwood

Village, Colorado, for amici curiae American Association of Pro-Life

Obstetricians & Gynecologists, Donna Harrison, M.D., Iowa Right to Life,

and Susan Thayer.

Matthew F. Heffron and Christine F. Delgado of Brown & Brown,

P.C., L.L.O., Omaha, Nebraska, Patrick D. Smith of Bradshaw, Fowler,

Proctor & Fairgrave, P.C., Des Moines, and Thomas Brejcha of Thomas

More Society, Chicago, Illinois, for amici curiae Catholic Medical

Association, Catholic Medical Association—Des Moines Guild, Catholic

Medical Association—St. Thomas Aquinas Guild of the Quad Cities,

Iowans for Life, and Women’s Choice Center of the Quad Cities. 3

WIGGINS, Justice.

In 2013, the Iowa Board of Medicine passed a rule establishing

standards of practice for physicians who prescribe or administer

abortion-inducing drugs. These standards require the physician to

personally perform a physical examination and to be physically present

when the abortion-inducing drug is provided. It is not disputed the rule

would have the effect of prohibiting telemedicine abortions in Iowa.

Planned Parenthood of the Heartland, Inc. and Dr. Jill Meadows,

M.D. (collectively Planned Parenthood) challenge the rule as both

improperly enacted and violative of the Iowa Constitution. For purposes

of this appeal, we will assume the Board properly enacted the rule and

did not violate any of the procedural or rulemaking provisions of Iowa

Code chapter 17A (2013), other than Planned Parenthood’s claim the rule

violates section 17A.19(10)(a), which provides an agency’s action is

invalid when “substantial rights of the person seeking relief have been

prejudiced” and the action is “[u]nconstitutional on its face or as

applied.” Iowa Code § 17A.19(10)(a). We will therefore focus on the

constitutional question.

The Board has conceded the Iowa Constitution provides a right to

an abortion that is coextensive with the right available under the United

States Constitution. Planned Parenthood argues the Iowa Constitution

affords a broader right, and we should therefore apply a strict scrutiny

analysis under the Iowa Constitution to the rule. We need not resolve

this question because we conclude, for the reasons stated herein, that

the Board’s rule violates the controlling “undue burden” test announced

by the United States Supreme Court as the federal constitutional test.

See Planned Parenthood of Se. Pa. v. Casey, 505 U.S. 833, 878–79, 112

S. Ct. 2791, 2821, 120 L. Ed. 2d 674, 715–16 (1992) (plurality opinion) 4

and Gonzales v. Carhart, 550 U.S. 124, 146, 158, 127 S. Ct. 1610, 1626–

27, 1633, 167 L. Ed. 2d 480, 502, 509–10 (2007). Thus, the contested

rule violates the Iowa Constitution under the less stringent Iowa

constitutional standard advanced by the Board. We therefore reverse the

decision of the district court as to the contested portions of the rule.

I. Background Facts and Proceedings.

On our de novo review, we find the following facts.

A. Medication Abortions. In 2000, the United States Food and

Drug Administration (FDA) approved the distribution and use of

mifepristone in the United States. Mifepristone, also known as RU–486,

is a prescription drug that terminates a pregnancy by detaching the

gestational sac from the uterine wall. In the clinical trials, the woman

returned two to four days later and took a second medication,

misoprostol, which induced contractions to complete the medication

abortion.

Consistent with the clinical trial documents submitted in support

of the application for approval of the drug, the FDA label indicated the

appropriate treatment regimen was to administer 600 mg of mifepristone

orally, followed two days later by 0.4 mg of misoprostol administered

orally. Additionally, the label indicated the patient should take the

mifepristone within the first seven weeks of pregnancy.

Once the FDA approves a drug, the FDA does not prohibit

physicians from using the drug in a different manner than the label

provides—otherwise known as “off-label” use. See U.S. Food & Drug

Admin., “Off-Label” and Investigational Use of Marketed Drugs, Biologics,

and Medical Devices–Information Sheet, available at

www.fda.gov/regulatoryinformation/guidances/ucm126486. Off-label 5

use means the safety and effectiveness of the dosing regimen has not

been established by the FDA.

Following FDA approval, additional studies led to the development

of new protocols for administering these drugs. The new off-label method

changed the dosage amounts of the drugs, lowering the amount of

mifepristone from 600 mg to 200 mg and increasing the amount of

misoprostol from 0.4 mg to 0.8 mg. The new method also changed the

administration of misoprostol from oral ingestion to buccally—placing

the pill between the cheeks and gums. The studies also showed this

method was safe and effective for use within the first nine weeks of

pregnancy.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Roe v. Wade
410 U.S. 113 (Supreme Court, 1973)
Planned Parenthood of Southeastern Pa. v. Casey
505 U.S. 833 (Supreme Court, 1992)
Gonzales v. Carhart
550 U.S. 124 (Supreme Court, 2007)
Armstrong v. State
1999 MT 261 (Montana Supreme Court, 1999)
Valley Hospital Ass'n v. Mat-Su Coalition for Choice
948 P.2d 963 (Alaska Supreme Court, 1997)
Pro-Choice Mississippi v. Fordice
716 So. 2d 645 (Mississippi Supreme Court, 1998)
Committee to Defend Reproductive Rights v. Myers
625 P.2d 779 (California Supreme Court, 1981)
Women of the State v. Gomez
542 N.W.2d 17 (Supreme Court of Minnesota, 1995)
Taylor v. Kurapati
600 N.W.2d 670 (Michigan Court of Appeals, 1999)
Mahaffey v. Attorney General
564 N.W.2d 104 (Michigan Court of Appeals, 1997)
Moe v. Secretary of Administration & Finance
417 N.E.2d 387 (Massachusetts Supreme Judicial Court, 1981)
Planned Parenthood of Middle Tennessee v. Sundquist
38 S.W.3d 1 (Tennessee Supreme Court, 2000)
Hope v. Perales
634 N.E.2d 183 (New York Court of Appeals, 1994)
Planned Parenthood of Arizona v. William Humble
753 F.3d 905 (Ninth Circuit, 2014)
Planned Parenthood of Wisconsin, Inc. v. Van Hollen
738 F.3d 786 (Seventh Circuit, 2013)
MKB Management Corp. v. Burdick
2014 ND 197 (North Dakota Supreme Court, 2014)
Planned Parenthood Southeast Ohio Region v. DeWine
696 F.3d 490 (Sixth Circuit, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Amended August 18, 2015 Planned Parenthood of the Heartland, Inc. and Jill Meadows v. Iowa Board of Medicine, Counsel Stack Legal Research, https://law.counselstack.com/opinion/amended-august-18-2015-planned-parenthood-of-the-heartland-inc-and-jill-iowa-2015.